Ctxt Pty Limited

Beijing University of Technology

Walter and Eliza Hall Institute of Medical Research

Monash University

H Rachel Lagiakos

Michelle Ang Camerino

Scott Raymond Walker

Richard Charles Foitzik

Paul Anthony Stupple

Benjamin Joseph Morrow

Ylva Elisabet Bergman

John Feutrill

Jonathan Bayldon Baell

Danny Ganame

Romina Lessene

Ylva Elisabet Bergman Bozikis

Graeme Irvine Stevenson

Huu Nghi Nguyen

Timothy John Thomas

David J Leaver

Catherine Fae Hemley

Benjamin L Cleary

Anne Kathrin Voss

Bilal Nadeem Sheikh

A compound of formula (I), or a pharmaceutical salt thereof:

Compounds

Compound of formula I: wherein: where Ris H or F;  where Xis either CRor N, where Ris H or F; Xis either CRor N, where Ris selected from H, Me, Cl, F OMe; Xis either CH or N; Xis either CRor N, where Ris H or F; where only one or two of X, X, Xand Xmay be N; and

Aryl sulfonohydrazides

A compound of formula (I) wherein: Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris either H or Me; Ris either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Tetrahydroisoquinoline derived PRMT5-inhibitors

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris either H or Me; Ris either H or Me; Rand Rare independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; Ris H or Me; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand R(if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris selected from OH, &#x2014;NH, &#x2014;C(&#x2550;O)NH, and &#x2014;CHOH; Ris either H or Me; Ris either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors

Growing community of inventors

Victoria, Australia

H Rachel Lagiakos